Trade Summary

6 days ago, Aslan Fred, serving as CEO at Artiva Biotherapeutics, Inc. (ARTV), sold 27,116 shares at $9.01 per share, for a total transaction value of $244,253.00. Following this transaction, Aslan Fred now holds 1,535,082 shares of ARTV.

This sale represents a 2.00% decrease in Aslan Fred's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, May 19, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, May 19, 2026 at 9:50 PM ET, meaning the disclosure happened on the same day as the trade.

Artiva Biotherapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.